Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Truncated Bid gene therapy targets breast cancer
March 16th, 2006
According to recent research from the United States, truncated Bid gene therapy targets breast cancer. "We studied the efficiency of the proapoptotic factor tBid, targeted to tumor cells using the promoters of the hTERT, Survivin and Muc1 genes, in killing breast cancer cells," wrote I. Kazhdan and colleagues, University of Texas, San Antonio. "tBid is the active fragment of the proapoptotic protein Bid and is generated in response to death receptor activation. When placed under control of a strong CMV promoter, tBid was highly efficient in killing breast cancer cells." The researchers explained, "When expression of tBid was...
Source: Women's Health Weekly (2006-03-16)
|
